Implantable device for long-term delivery of drugs
A device for sustained delivery of a poorly water soluble drug is described. A drug reservoir within the device, when in operation, contains an aqueous suspension of the drug mixed with a suspension of an excipient that, in one embodiment, generates acidic groups for a sustained period of time to maintain a desired pH in the aqueous suspension that in turn provides a constant concentration of a soluble form of the drug.
1. A method for delivering a sparingly water soluble drug into an environment of use, comprising:
providing a device comprising a porous partition with pores having a pore size and with a porosity, a reservoir and a formulation contained in the reservoir, the formulation comprising a sparingly water soluble drug having a soluble form and an insoluble form and a solubility-modifying excipient that generates acidic groups for a period of between about 2-12 months to provide, when the formulation is hydrated, a concentration of drug in the soluble form that is released across the porous partition and a concentration of drug in the insoluble form that is retained by the porous partition, and
delivering a therapeutic dose of the drug for the period, wherein delivering the therapeutic dose is dependent on pH of the drug formulation and independent of pore size of the porous partition with said porosity.
2. The method according to claim 1 , wherein the excipient is a biocompatible, bioerodible polymer.
3. The method according to claim 2 , wherein the polymer is selected from the group of polylactides, polyglycolides, copolymers thereof, and polyethyleneglycol.
4. The method according to claim 2 , wherein the polymer is a co-polymer of polylactic acid and polyglycolic acid monomeric units, wherein the polylactic acid content is between about 50% to 100%.
5. The method according to claim 1 , wherein the solubility-modifying excipient is an erodible polymer or a degradable polymer.
6. The method according to claim 5 , wherein the polymer is polymerized from a monomer selected from the group consisting of lactic acid, glycolic acid, lactide, glycolide, ethylene oxide and ethylene glycol.
7. The method according to claim 5 , wherein the polymer is a poly(lactic-co-glycolic acid) copolymer.
8. The method according to claim 1 , wherein the solubility-modifying excipient is water insoluble.
9. The method according to claim 8 , wherein the solubility-modifying excipient is retained by the porous partition.
10. The method according to claim 1 , wherein the solubility-modifying excipient is a water insoluble polymer.
11. The method according to claim 10 , wherein the solubility-modifying excipient undergoes hydrolysis to form a water-soluble monomer.
12. The method according to claim 1 , wherein said drug is a neuroleptic agent.
13. The method according to claim 12 , wherein the neuroleptic agent is risperidone, 9-hydroxyrisperidone, olanzapine, or a pharmaceutically acceptable salt thereof.
14. The method according to claim 1 , wherein said drug is risperidone.
15. The method according to claim 1 , wherein the drug is selected from the group consisting of buprenorphine, paliperidone, asenapine, haloperidol, aripiprazole, and pharmaceutically acceptable salts thereof.
16. A method for treating a patient with a sparingly water soluble drug, comprising:
implanting a device comprising a porous partition with pores having a pore size and with a porosity, a reservoir and a formulation contained in the reservoir, the formulation comprising a sparingly water soluble drug having a soluble form and an insoluble form and a solubility-modifying excipient that generates acidic groups for a period of between about 2-12 months to provide, when the formulation is hydrated to form an aqueous suspension, a concentration of drug in the soluble form that is released across the porous partition and a concentration of drug in the insoluble form that is retained by the porous partition, and
delivering a therapeutic dose of the drug for the period, wherein delivering the therapeutic dose is dependent on pH of the drug formulation and independent of pore size of the porous partition with said porosity.
17. The method according to claim 16 , wherein the device is implanted subcutaneously.